Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)

NCT00308269 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Vintafolide IV Bolus
DRUG: Vintafolide IV Infusion

Sponsor

Endocyte